Charles Schwab Investment Management Inc Pyxis Oncology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 129,761 shares of PYXS stock, worth $219,296. This represents 0.0% of its overall portfolio holdings.
Number of Shares
129,761
Previous 129,761
-0.0%
Holding current value
$219,296
Previous $429,000
10.96%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding PYXS
# of Institutions
101Shares Held
28.2MCall Options Held
539KPut Options Held
54.1K-
Deep Track Capital, LP Greenwich, CT4.18MShares$7.07 Million0.57% of portfolio
-
Laurion Capital Management LP New York, NY3.63MShares$6.13 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$4.71 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$4.11 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$3.22 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $59.3M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...